FA
MCRB icon

FDx Advisors’s Seres Therapeutics MCRB Stock Holding History

FDx Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-491
Closed -$234K – 837
2021
Q2 		$234K Sell
491
-185
-27% -$78.1K 0.01% 737
2021
Q1 		$279K Sell
676
-41
-6% -$18.9K 0.01% 653
2020
Q4 		$351K Sell
717
-28
-4% -$16.4K 0.01% 526
2020
Q3 		$422K Buy
745
+227
+44% +$75.5K 0.02% 416
2020
Q2 		$49K Buy
+518
New +$45.4K ﹤0.01% 569

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FDx Advisors's MCRB Position: Q3 2021 in Review

FDx Advisors sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 491 shares — an estimated $234K sold.

FDx Advisors first reported a position in MCRB in Q2 2020 and held it in 5 quarters. The position peaked at $422K in Q3 2020. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • FDx Advisors reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • FDx Advisors sold 491 Seres Therapeutics shares in Q3 2021, an estimated $234K.
  • FDx Advisors first reported a position in Seres Therapeutics in Q2 2020 and held it in 5 quarters.
  • FDx Advisors's Seres Therapeutics position peaked at $422K in Q3 2020.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on FDx Advisors's 13F filing for Q3 2021, filed 8 Oct 2021.